A Safe, Scalable Antiviral Platform Was Positively Evaluated by NIH ACTIV. Why Is It Still Ignored in the Ebola Emergency?
A safe, scalable dsRNA antiviral with NIH ACTIV support already exists—yet it remains absent from the Ebola response. IBDV’s human safety, manufacturability, and broad antiviral profile demand urgent BSL 4 evaluation as the outbreak accelerates.